Hypoxia and oxidative stress in cerebral circulation insufficiency — effective ways of correction
This article is in "Library" - "Neurology" section.
Author:
E.I. CHUKANOVA, A.S. CHUKANOVA, D.M. RODIONOVA
Pirogov Russian National Research Medical University, Moscow, Russia
Pharmacotherapy in post-stroke rehabilitation
This article is in "Library" - "Therapy" section.
Author:
R.KH. LYUKMANOV, A.A. RIMKEVICHUS, E.V. GNEDOVSKAYA, N.A. SUPONEVA
Research Center of Neurology, Moscow, Russia
Pharmacotherapy in post-stroke rehabilitation
Author:
R.KH. LYUKMANOV, A.A. RIMKEVICHUS, E.V. GNEDOVSKAYA, N.A. SUPONEVA
Research Center of Neurology, Moscow, Russia
Summary:
The article presents data on the conditions of use and efficacy of botulinum toxin preparations, oral muscle relaxants, selective serotonin reuptake inhibitors, acetylcholinesterase inhibitors and a glutamatergic transmission modulator in post-stroke neurorehabilitation, and provides recommendations for their rational and safe use. The clinical efficacy of Mexidol, which has a polymodal effect on a wide range of post-stroke disorders, especially in long-term sequential therapy, is discussed. A complex use of post-stroke rehabilitation methods with the determination of individual tactics based on the clinical picture of the patient and the defined rehabilitation goals is recommended. The inclusion of Mexidol in the complex therapy of patients with stroke consequences for tasks related to improving motor, affective and cognitive functions and self-care and quality of life looks promising. It is necessary to continue high-quality clinical studies to assess the pharmaceuticals efficacy in relation to post-stroke disorders.
Keywords: stroke, hemiparesis, spasticity, depression, dementia, neurorehabilitation, pharmacotherapy.
Use of Mexidol in the Therapy of Primary Open-angle Glaucoma
This article is in "Library" - "Ophthalmology" section.
Author:
I.A. LOSKUTOV, O.M. ANDRYUKHINA, A.A. KOVRIZHKINA
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Use of Mexidol in the Therapy of Primary Open-angle Glaucoma
Author:
I.A. LOSKUTOV, O.M. ANDRYUKHINA, A.A. KOVRIZHKINA
M.F. Vladimirsky Moscow Regional Research Clinical Institute
Summary:
The article focuses on the complex therapy of primary open-angle glaucoma, namely the application and understanding of the principles of neuroprotection in the pathogenesis of the development of glaucomatosis optic neuropathy. Various biochemical reactions involved in the apoptosis of the retinal nerve fiber layer and in neurodegeneration processes are described. In Russian Federation, a reference antioxidant with a multimodal mechanism of action – Mexidol (ethylmethylhydroxypyridine succinate) has been registered and actively used actively used. Due to its unique complex molecule – the pyrimidine base and succinic acid derivative of compounds, Mexidol has high bioavailability and the ability to pass through the hematoencephalic barrier. The presence of succinate in the molecule also enhances the antioxidant effect, which is a fundamental difference between the drug and other antioxidant analogues presented on Russian pharmaceutical market. The mechanism of action of Mexidol is based on antioxidant, antihypoxant and membraneotropic effects. Given the wide range of action of this molecule, Mexidol acts on different links of oxidative stress, which is justifed in the complex treatment of primary open-angle glaucoma, in connection with which the drug is included in the standards of medical care in patients with glaucoma. The analysis of publications of the results of the study of ethylmethylhydroxypyridine succinate by various authors in primary open-angle glaucoma of stages I–III was carried out. A sequential scheme of therapy with Mexidol has been developed, with proven efficacy, slowing down neurodegeneration processes and stabilizing visual functions in patients with primary open-angle glaucoma.
Key words: glaucoma, Mexidol, antioxidant, neuroprotection, oxidative stress.
Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications
This article is in "Library" - "Neurology" section.
Author:
E.L. PUGACHEVA
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
Efficacy of Mexidol in patients with type 2 diabetes mellitus with neurological complications
Author:
E.L. PUGACHEVA
Pavlov First Saint Petersburg State Medical University, St. Petersburg, Russia
Summary:
Objective. Complications of Diabetes mellitus (DM), depends on the severity of hypoxic tissue damage. Amelioration of hypoxic injury may improve current therapy approaches and enhance the quality of life in patient’s cohort suffered from DM. Material and methods. 30 pts which DM were enrolled into the study. Mexidol forte, was given IV 500 mg/day for 14 days, follow up with oral administration 250 TID. Clinical impression, neuropsychological scales and biochemical blood tests were recorded. Results. Mexidol administration improved cognitive functions, decreased the level of asthenia, depressia, improved sleep disturbances, and normalized biochemical landscape. Conclusions. Mexidol administration for the period 75 days may serve as important therapeutic supplementation and considered as adjunctive therapy in the treatment of patients with DM. Keywords: Diabetes mellitus, hypoxia, oxidative stress, antioxidants, neurotransmitters, antihypoxive medications, Mexidol.
Neurological manifestations of postcovid syndrome
This article is in "Library" - "COVID-19" section.
Author:
P.R. KAMCHATNOV1, R.A. CHEREMIN2, L.A. SKIPETROVA2, A.V. CHUGUNOV1
1N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
2Center of Speech Pathology and Neurorehabilitation, Moscow, Russia
Neurological manifestations of postcovid syndrome
Author:
P.R. KAMCHATNOV1, R.A. CHEREMIN2, L.A. SKIPETROVA2, A.V. CHUGUNOV1
1N.I. Pirogov Russian National Research Medical University, Moscow, Russia;
2Center of Speech Pathology and Neurorehabilitation, Moscow, Russia
Summary:
The problem of postcovid syndrome (PCS) attracts great interest due to the wide prevalence and variety of clinical manifestations. The main neurological manifestations of PCS are considered. The information about the proposed mechanisms of the formation of PCS is given. The possibility of using the drug Mexidol for the treatment of patients with PCS is discussed. Keywords: COVID‑19, postcovid syndrome, cognitive impairment, chronic cerebral ischemia, Mexidol, treatment.
Study of the efficacy and safety of sequential use of the drugs Mexidol and Mexidol FORTE 250 in the treatment of stroke
This article is in "Library" - "Neurology" section.
Author:
S.M. KARPOV1, M.YU. MOROZOVA2, K.A. MURAVYOV2, I.A. VYSHLOVA1, F.S. KANTEMIROVA3
1Stavropol State Medical University, Stavropol, Russia;
2City Clinical Hospital No. 3, Stavropol, Russia;
3Georgievsky Medical Academy, Simferopol, Russia